Physician profile
Tomer M Mark
NPI 1891981346
$95,683.91
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $8,799 · 2021: $22K · 2022: $746.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34,571.22 | 2019 | |
| Celgene Corporation | $24,352.34 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $17,976.78 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $5,880.00 | 2020 | |
| Genzyme Corporation | $4,914.89 | 2019-2022 | |
| Genentech, INC. | $2,901.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,827.36 | 2020 | |
| Glaxosmithkline, LLC. | $2,194.42 | 2020-2021 | |
| Janssen Biotech, INC. | $49.02 | 2019 | |
| Beigene USA, INC. | $16.76 | 2022 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomer Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.